Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Insulin Tregopil in Type 1 Diabetes
NCT04141423Phase 1Terminated
- Sponsor
- Biocon
- Start
- Oct 2019
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin tregopil in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Biocon. Primary endpoints: Adverse events (AEs), Laboratory safety parameters and 3 more. Started Oct 2019; status: terminated.
02
Drugs
insulin tregopil
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04141423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141423.